Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $18.82 (market cap $8.59B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 4.7× Recursion Pharmaceuticals Inc's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| NCLH | RXRX | |
|---|---|---|
Market Cap | $8.59B | $1.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.94 | $6.79 |
52-Week Low | $14.79 | $2.84 |
Enterprise Value | $23.40B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $18.55, down 3.64% today, amid a bearish technical signal. The company reported Q2 2026 EPS of $0.48, beating estimates, but faces headwinds from high fuel costs and soft demand. Revenue growth is steady, with 2025 revenue at $9.83B, and profitability metrics like a 7.49% net income margin show resilience. Analyst consensus is bullish with a $20.73 price target, though recent news highlights execution risks and macroeconomic pressures.
The outlook is mixed: strong fundamentals and analyst support suggest upside potential, but near-term volatility from cost pressures and travel demand uncertainty poses risks. Investors should weigh the attractive valuation against operational challenges in the cruise industry.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
